SciSparc Ltd.
Index- P/E- EPS (ttm)-3.05 Insider Own6.47% Shs Outstand3.53M Perf Week-13.46%
Market Cap1.59M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float3.30M Perf Month-39.02%
Income- PEG- EPS next Q- Inst Own0.84% Short Float / Ratio3.54% / 0.11 Perf Quarter-38.45%
Sales- P/S- EPS this Y- Inst Trans- Short Interest0.12M Perf Half Y-41.59%
Book/sh0.86 P/B0.52 EPS next Y- ROA- Target Price- Perf Year-88.40%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range0.47 - 5.00 Perf YTD-40.44%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-91.00% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low-4.26% ATR0.06
Employees3 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)23.65 Volatility8.56% 9.28%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.06 Prev Close0.48
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume1.06M Price0.45
Recom- SMA20-24.71% SMA50-41.75% SMA200-57.67% Volume63,667 Change-6.25%
Mar-28-23 09:00AM
Mar-10-23 04:15PM
Mar-09-23 07:30AM
Mar-06-23 07:45AM
Feb-27-23 09:11AM
08:45AM Loading…
Feb-23-23 08:45AM
Feb-22-23 08:00AM
Feb-17-23 08:00AM
Feb-15-23 08:30AM
Jan-25-23 08:30AM
Jan-23-23 02:15PM
07:30AM Loading…
Jan-18-23 07:30AM
Jan-17-23 08:30AM
Jan-09-23 08:30AM
Jan-05-23 09:00AM
Dec-14-22 09:15AM
Dec-07-22 08:40AM
Nov-29-22 08:00AM
Nov-15-22 10:25AM
Nov-08-22 07:00AM
Nov-07-22 08:45AM
Nov-01-22 08:30AM
Oct-28-22 07:45AM
Oct-12-22 09:00AM
Sep-30-22 07:00AM
08:30AM Loading…
Sep-22-22 08:30AM
Sep-14-22 07:35AM
Aug-24-22 07:30AM
Aug-19-22 06:45AM
Aug-18-22 08:15AM
Aug-15-22 08:30AM
Aug-12-22 08:00AM
Aug-08-22 08:55AM
Aug-01-22 09:30AM
Jul-21-22 07:22AM
Jul-08-22 08:30AM
Jul-07-22 08:30AM
Jul-06-22 09:31AM
Jun-29-22 08:30AM
Jun-23-22 09:30AM
Jun-15-22 08:30AM
Jun-09-22 08:30AM
Jun-07-22 08:30AM
Jun-02-22 09:55AM
Jun-01-22 04:07PM
May-31-22 08:30AM
May-27-22 09:15AM
May-26-22 08:30AM
May-24-22 08:30AM
May-10-22 08:30AM
May-02-22 08:41AM
Mar-31-22 09:30AM
Mar-30-22 08:30AM
Mar-17-22 08:00AM
Mar-10-22 08:30AM
SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. SciSparc Ltd. has collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.